A phase II study to evaluate the safety, pharmacodynamics and efficacy of entinostat in combination with nivolumab plus ipilimumab in patients with renal cell carcinoma previously treated with nivolumab plus ipilimumab or nivolumab alone.-MedSci.cn

A phase II study to evaluate the safety, pharmacodynamics and efficacy of entinostat in combination with nivolumab plus ipilimumab in patients with renal cell carcinoma previously treated with nivolumab plus ipilimumab or nivolumab alone.

Pili, R; Adra, N; Logan, TF; Burney, H; Atkins, MB

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 ():

科室
- - 订阅+
  - 更多科室
工具
服务